JAMA OPHTHALMOLOGY, vol.139, pp.769-776, 2021 (SCI-Expanded, Scopus)
IMPORTANCE Poor adherence or persistence to treatment can be a barrier to optimizing clinical practice (real-world) outcomes to intravitreal injection therapy in patients with neovascular age-related macular degeneration (nAMD). Currently, there is a lack of consensus on the definition and classification of adherence specific to this context.